ValuentumAd

Official PayPal Seal
Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Oct 30, 2019
Tech Earnings Roundup: AAPL, FB, GOOG
Several large tech companies reported earnings this week including three of the top holdings in our Best Ideas Newsletter and Dividend Growth Newsletter portfolios.
Oct 30, 2019
Johnson & Johnson Announces New Test Results That Reveal No Traces of Asbestos in Johnson Baby Powder Products
Image Source: Johnson & Johnson – February 2019 CAGNY IR Presentation. Major retailers including Walmart, Rite Aid Corp, and CVS Health pulled Johnson Baby Powder products from their shelves after the announcement by the FDA. Johnson & Johnson is hoping that by fighting back it can preserve its brand power, revenues, and position on retailer’s shelves once it’s all said and done. We will continue to monitor this situation going forward and would like to note that Johnson & Johnson, potential legal liabilities aside, raised its full-year guidance for 2019 multiple times this year highlighting the underlying demand for its vast array of healthcare-related offerings. That supports a nice free cash flow growth trajectory.
Oct 20, 2019
Johnson & Johnson’s Talc Problems Hit Another Bump
Image Shown: Johnson & Johnson’s embattled ‘Baby Care’ segment performed poorly during the third quarter of 2019. Image Source: Johnson & Johnson – IR Presentation. Johnson & Johnson was back in the news Friday October 18 when the company announced it was voluntarily recalling “a single lot” of its embattled Johnson’s Baby Powder product in the US due to alleged asbestos contamination risks. The US Food and Drug Administration tested a single bottle from this lot, according to Johnson & Johnson, with the federal regulator noting that sub-trace levels (no greater than 0.00002%) of chrysotile asbestos had been detected in the bottle. Johnson & Johnson plans to vigorously contest these allegations and maintains that its talc products don’t contain asbestos.
Oct 15, 2019
Johnson & Johnson Raises Full-Year Guidance Yet Again
Mounting legal liabilities have been weighing negatively against Johnson & Johnson and its stock price over the past year as investors fret about the size of these potential settlements/judgements. We see the firm’s latest quarterly performance and guidance increase for 2019 as validation of the strength of Johnson & Johnson’s broad-based healthcare business model. Once the market gets a better idea of Johnson & Johnson’s total potential legal liabilities, shares could begin to converge towards their intrinsic value given the underlying strength in the firm’s businesses. Our fair value estimate for shares of JNJ stands at ~$150 per share.
Sep 26, 2019
Hold ‘em or Fold ‘em?
Let’s talk Cardinal Health, Hanesbrands, Ford and Verint in this piece. Our best ideas are ideas in the newsletter portfolios. Unlike other widely followed strategies, the Valuentum strategy likes to capture the entire pricing cycle on an idea. We don’t “operate” in ideas only below the ‘undervalued’ line, but we like to let our winners run to when they are overvalued and showing signs of technical/momentum deterioration.
Sep 20, 2019
Dividend Increases/Decreases for the Week Ending September 20
Let's take a look at companies that raised/lowered their dividend this week.
Sep 11, 2019
Economic Roundtable: “Value” Versus “Growth” Rotation
“This kind of trading activity could be setting the stage for a big quant fund blow up, if the kind of leverage it takes to move the markets to this magnitude was applied. All it may take is for the B/M “value” factor to continue to suffer in the coming 12-18 months--it’s possible we could see a few quant firms go belly up. My guess is that market participants are paying very close attention to this activity, and if they “smell blood,” things could get ugly.” – Brian Nelson, CFA
Sep 3, 2019
Triple-A Rated J&J’s Opioid Liabilities Likely More Than Priced In
Image Source: J&J. Shares of J&J have settled into the high-$120s at the time of this writing, well below our ~$150 fair value estimate. We’re going to stick with J&J in both the Dividend Growth Newsletter portfolio and Best Ideas Newsletter portfolio at this time.
Jun 4, 2019
VBI 9-Rated AmerisourceBergen Now On Our Radar
Image Source: AmerisourceBergen Corpration -- IR Presentation. Let's take a look at VBI 9-rated stock AmerisourceBergen, a pharmaceutical sourcing and distribution company that yields 2% as of this writing. We like AmerisourceBergen's dividend growth story, strong free cash flow generation, guidance raise, and relatively low net debt load. We'll also cover AmerisourceBergen's downside risks as well as its upside potential. Shares appear undervalued as things stand today, with ABC trading below the low end of our fair value estimate range.
May 28, 2019
Our Reports on Stocks in the Healthcare Products Distributors Industry
Image Source: Express Scripts. We have dropped coverage of the Healthcare Products Distributors industry: ABC, CAH, HSIC, MCK, PDCO.


The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.